Question 1

What is Qfitlia?

Accepted Answer

Qfitlia is a targeted therapy classified as a kinase inhibitor. This medication works by interfering with the signaling pathways of specific proteins involved in the growth of new blood vessels that tumors need to survive and expand.

By inhibiting these specific proteins, the medication helps to restrict the blood supply to cancer cells and slows the overall progression of the disease. It is designed to target the underlying mechanisms that allow cancer to thrive.

Question 2

What is Qfitlia used for?

Accepted Answer

Qfitlia is used to treat growth hormone deficiency .

Question 3

How does Qfitlia work?

Accepted Answer

Mechanism of Action

Qfitlia is a type of medication known as a bispecific T-cell engager. It is designed to act as a bridge between the body's immune system and cancer cells.

The medication works by binding to two specific targets simultaneously:

DLL3: This is a protein found on the surface of many small cell lung cancer cells.

CD3: This is a protein found on T-cells, which are a type of white blood cell that helps the body fight infection and disease.

By attaching to both the cancer cell and the T-cell at the same time, Qfitlia brings them into close contact. This proximity triggers the T-cell to become active and release substances that kill the cancer cell. This process helps the immune system specifically target and eliminate cancer cells that express the DLL3 protein.

Question 4

What are the active ingredients in Qfitlia?

Accepted Answer

The active ingredient in Qfitlia is fitusiran .

Question 5

What are the side effects of Qfitlia?

Accepted Answer

The most common side effects reported by people taking Qfitlia include:

Fatigue or extreme tiredness

Fever

Changes in the sense of taste

Decreased appetite

Muscle, bone, or joint pain

Constipation

Nausea

Low red blood cell counts (anemia)

Qfitlia can cause serious or life-threatening side effects. Seek medical help immediately if you experience symptoms of the following:

Cytokine Release Syndrome (CRS): Symptoms may include fever, chills, dizziness, fast heartbeat, or trouble breathing.

Neurologic Toxicity: This may cause confusion, tremors, difficulty speaking, headaches, or extreme sleepiness.

Liver Problems: Signs include yellowing of the skin or eyes, dark urine, or pain in the upper right side of the stomach.

Infections: Fever, cough, or pain during urination may indicate a serious infection.

Low Blood Cell Counts: This can increase the risk of bleeding or infection.

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Qfitlia?

Accepted Answer

Qfitlia belongs to the tricyclic antidepressant drug class.

Question 7

What is the dosage of Qfitlia and how do I take it?

Accepted Answer

How Qfitlia is Given

Qfitlia is administered as an infusion into a vein ( intravenous or IV ) by a healthcare professional in a clinical setting, such as a hospital or infusion center. The infusion process usually takes several hours to complete.

Before each treatment, your healthcare provider will likely give you other medications to help prevent certain side effects. These premedications often include drugs to prevent nausea , vomiting , and allergic reactions , and are typically administered shortly before the Qfitlia infusion begins.

Dosing Schedule

This medication is usually given in repeating cycles. Your healthcare provider will determine the specific frequency of your infusions and the total number of treatment cycles you will receive based on your condition and how your body responds to the medicine.

Missed Dose

Because this medication is administered by a healthcare professional, it is important to keep all scheduled appointments. If you miss an appointment for an infusion, contact your doctor or clinic as soon as possible to reschedule your treatment. Maintaining the prescribed schedule helps ensure the medication works effectively.

Question 8

Is Qfitlia safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

There is limited information regarding the use of Qfitlia in pregnant women. Based on its mechanism of action, this medication may cause harm to a developing fetus. If you are pregnant or planning to become pregnant, you should discuss the potential risks and benefits with your healthcare provider before starting treatment.

Individuals who are able to become pregnant are typically advised to use effective birth control during treatment with Qfitlia and for at least 15 hours after the final dose. Notify your doctor immediately if you become pregnant while receiving this medication.

Breastfeeding

It is not known whether Qfitlia passes into human breast milk or how it might affect a nursing infant. Because of the potential for serious side effects, it is generally recommended that you do not breastfeed during treatment and for at least 15 hours after your last dose. Consult your healthcare team to determine the safest way to feed your baby during this time.

Question 9

What forms and strengths does Qfitlia come in?

Accepted Answer

Qfitlia is supplied as a sterile, preservative-free solution for injection into the eye (intravitreal injection). It is available in the following form:

Single-dose glass vial

The solution is clear to slightly opalescent and colorless to pale yellow. Each vial is intended for a single treatment in one eye. This medication must be administered by a qualified healthcare professional.

Question 10

What is the FDA approval status of Qfitlia?

Accepted Answer

FDA Approval Status

The U.S. Food and Drug Administration (FDA) approved Qfitlia in October 2024. It is recognized as a first-in-class treatment, meaning it uses a new mechanism of action to help blood clot by targeting the tissue factor pathway inhibitor (TFPI).

Approved Indications

Qfitlia is approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older who have:

Hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors.

Hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.

Regulatory Designations

During its development, Qfitlia received Orphan Drug and Fast Track designations from the FDA. These programs are designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and address unmet medical needs for rare diseases. The approval was based on clinical trial data showing that the medication significantly reduced the rate of annual bleeding episodes compared to previous standard treatments.

Question 11

What should I know about Qfitlia and cost?

Accepted Answer

Insurance and Coverage

The out-of-pocket cost for Qfitlia is primarily determined by your health insurance plan. Coverage levels vary between private insurance, Medicare, and Medicaid. Most insurance providers require prior authorization before they will approve coverage for this medication.

Administration Costs

Because Qfitlia is administered as an intravenous infusion by a healthcare professional, there are additional costs beyond the price of the medication itself. These may include:

Fees for the hospital or clinic facility.

Professional fees for nursing and medical staff.

Costs for monitoring and supportive care during and after the infusion.

Financial Assistance

Financial assistance programs may be available to help eligible patients manage the cost of treatment. These programs are often provided by the manufacturer or through non-profit organizations. Patients and caregivers should speak with their healthcare provider or a financial counselor at the treatment center to explore available support options and copay assistance.

Qfitlia

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Price Information

FAQ

Found an Error?